Hims & Hers Health (HIMS) AI Stock Analysis

• Market Cap: $12.55B
• Dividend Yield: N/A
• Average Volume (3M): 37.04M
• Price to Earnings (P/E): 64.0
• Beta (1Y): 2.72
• Revenue Growth: 85.99%
• EPS Growth: N/A
• Country: US
• Employees: 1,637
• Sector: Consumer Defensive
• Sector Strength: 65
• Industry: Household & Personal Products
• EPS (TTM): 0.17
• Shares Outstanding: 217,641,950
• 10 Day Avg. Volume: 47,667,021
• 30 Day Avg. Volume: 37,036,785
• PEG Ratio: -0.07
• Price to Book (P/B): 10.95
• Price to Sales (P/S): 3.54
• P/FCF Ratio: 26.33
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 6.31
• Enterprise Value/Gross Profit: 8.28
• Enterprise Value/Ebitda: 88.01
• 1Y Price Target: $48.75
• Price Target Upside: -4.51% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 10

• Rating: 77 Outperform
• Price Target: $72.00 ▲(41.04% Upside)

Hims & Hers Health's strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company's robust revenue growth, strategic partnerships, and expansion efforts support its growth trajectory. However, the high P/E ratio suggests that the stock may be overvalued, posing a risk if growth expectations are not met. Technical indicators support a bullish trend, adding to the positive outlook.

Positive Factors

Brand recognition

HIMS is the category leader in U.S. direct-to-consumer sexual health, benefiting from the largest customer base and superior brand recognition.

Future growth infrastructure

HIMS is building the right infrastructure for future growth by investing behind new specialties, lab testing capabilities, and technology, while simultaneously targeting international expansion.

ZAVA contribution

HIMS is adding 'at least $50MM' of revenue from recently acquired ZAVA in the second half of the year.

Negative Factors

Competition

Elevated competition is likely to limit growth prospects in the sexual health business.

Regulatory risks

Potential litigation/regulatory risks may hinder HIMS's ability to offer personalized semaglutide.

Revenue decline

The company’s first revenue miss was driven by both the expected decline in GLP-1 revenue and the unexpected decline in 'core' revenue outside of GLP-1s.

Hims & Hers Health Business Overview & Revenue Model

Company Description

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

How the Company Makes Money

Hims & Hers Health generates revenue primarily through the sale of its products and services via its online platform. The company's business model includes a direct-to-consumer approach, where customers can subscribe to monthly plans for recurring shipments of prescription medications and personal care products. Revenue streams are diversified across various health categories, including sexual health, dermatology, mental health, and primary care. Key factors contributing to its earnings include its ability to leverage telemedicine to reduce costs and improve accessibility, its subscription-based model that ensures recurring revenue, and strategic partnerships with healthcare professionals and pharmaceutical companies to broaden its service offerings.

Hims & Hers Health Financial Statement Overview

Summary

Hims & Hers Health exhibits strong revenue growth and improved profitability metrics, supported by a solid balance sheet with low leverage and increasing equity. The company has effectively managed cash flows, ensuring positive free cash flow generation. While historical challenges such as negative earnings and equity should be considered, the current financial trajectory is positive, indicating a stable outlook.

Income Statement

Hims & Hers Health has demonstrated robust revenue growth and improving profitability. Over the TTM, total revenue increased significantly by 20.86% from the previous annual period. The company's gross profit margin stood at 74.73%, and the net profit margin improved to 9.21%. Additionally, the EBIT margin increased to 6.19%, indicating better operational efficiency. However, historical losses and fluctuating margins in previous years pose a potential risk.

Balance Sheet

The balance sheet shows a healthy equity position with an equity ratio of 61.58%, indicating strong financial stability. The debt-to-equity ratio is low at 0.12, reflecting conservative leverage. Return on equity improved to 29.92%, suggesting effective use of equity to generate profits. The increase in stockholders' equity over time highlights the company's capital strength. However, past negative equity and liabilities exceeding assets in earlier years should be noted.

Cash Flow

Hims & Hers Health's cash flow from operations has consistently improved, with a significant increase in free cash flow by 14.68% over the latest period. The operating cash flow to net income ratio is robust at 2.03, demonstrating strong cash generation relative to earnings. The company has maintained positive free cash flow, indicative of good cash management practices. Past periods of negative free cash flow and operational cash flow constraints may pose risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.01B	1.48B	872.00M	526.92M	271.88M	148.76M
Gross Profit	1.53B	1.17B	714.95M	408.72M	204.49M	109.45M
EBITDA	144.31M	78.99M	-19.94M	-61.22M	-110.97M	-14.09M
Net Income	193.60M	126.04M	-23.55M	-65.68M	-107.66M	-18.11M
Balance Sheet
Total Assets	1.88B	707.54M	441.19M	366.34M	420.58M	118.70M
Cash, Cash Equivalents and Short-Term Investments	1.14B	300.25M	220.98M	179.63M	247.27M	100.21M
Total Debt	1.04B	11.35M	9.95M	5.31M	5.48M	0.00
Total Liabilities	1.31B	230.82M	97.16M	54.60M	85.97M	265.57M
Stockholders Equity	562.70M	476.72M	344.03M	311.74M	334.62M	-146.87M
Cash Flow
Free Cash Flow	127.47M	198.33M	46.99M	-33.78M	-39.42M	-6.71M
Operating Cash Flow	261.63M	251.08M	73.48M	-26.53M	-34.41M	-2.48M
Investing Cash Flow	-81.50M	-19.05M	-12.11M	34.70M	-156.27M	-39.70M
Financing Cash Flow	813.68M	-107.84M	-11.47M	-33.13M	235.04M	47.74M

Hims & Hers Health Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 51.05
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIMS, the sentiment is Neutral. The current price of 51.05 is below the 20-day moving average (MA) of 55.37, below the 50-day MA of 53.70, and above the 200-day MA of 39.06, indicating a neutral trend. The MACD of 1.37 indicates Positive momentum. The RSI at 43.93 is Neutral, neither overbought nor oversold. The STOCH value of 5.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HIMS.

Hims & Hers Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HIMS	77 Outperform	$12.55B	63.99	41.88%	―	85.99%	―
ELF	71 Outperform	$6.23B	57.48	12.97%	―	18.61%	-21.36%
IPAR	69 Neutral	$3.81B	23.70	20.68%	2.65%	7.04%	13.52%
Sector *	63 Neutral	$20.32B	12.52	-7.33%	3.14%	2.92%	-10.01%
COTY	61 Neutral	$4.16B	40.12	-10.58%	―	-1.68%	-302.11%
EPC	57 Neutral	$954.23M	14.99	4.12%	2.71%	-2.92%	-43.06%
NUS	55 Neutral	$412.10M	―	-4.93%	2.93%	-11.85%	-1080.00%

Hims & Hers Health Corporate Events

Hims & Hers Health Reports Strong Q2 2025 Financial Growth

Hims & Hers Health, Inc. reported significant financial growth in the second quarter of 2025, with a 73% increase in revenue year-over-year, reaching $544.8 million. The company also saw a 31% increase in subscribers, totaling over 2.4 million, and a net income of $42.5 million. The company is focusing on expanding its capabilities, including enhancing personalization in pharmacies, expanding lab testing, and growing its international presence, which is expected to further strengthen its market position.

The most recent analyst rating on (HIMS) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.

Hims & Hers Health Annual Stockholders Meeting Results

On June 12, 2025, Hims & Hers Health, Inc. conducted its Annual Meeting of Stockholders where three proposals were voted on. The election of eight directors, the ratification of KPMG LLP as the independent registered public accounting firm, and the advisory approval of executive compensation were all passed, reflecting shareholder support for the company’s governance and financial strategies.

The most recent analyst rating on (HIMS) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.

Hims & Hers Health Issues $1 Billion in Notes

On May 13, 2025, Hims & Hers Health issued $1 billion in senior unsecured notes, which are equal in payment rights to the company’s existing and future senior unsecured debts but are subordinate to secured debts. These notes, maturing on May 15, 2030, offer conversion options into Class A common stock under specific conditions and include provisions for redemption and repurchase under certain corporate events. Additionally, the company engaged in capped call transactions to mitigate potential stock dilution from note conversions, with a cap price set at $89.95 per share, representing a 75% premium over the stock’s last reported sale price on May 8, 2025.

The most recent analyst rating on (HIMS) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.

Hims & Hers Announces $450M Convertible Notes Offering

On May 8, 2025, Hims & Hers Health, Inc. announced a proposed private offering of $450 million in Convertible Senior Notes due 2030, aimed at qualified institutional buyers. The proceeds from this offering are intended to support the company’s global expansion and investment in AI and personalized healthcare solutions, reflecting Hims & Hers’ strategic focus on scaling access to high-quality, personalized care. The offering is expected to enhance the company’s market positioning by funding organic growth and potential acquisitions, although no definitive acquisition agreements are in place at this time.